摘要
目的探讨卷曲螺旋结构域蛋白69(coiled-coil domain-containing protein 69,CCDC69)在乳腺癌组织中的表达情况及其与乳腺癌患者临床特征和预后之间的相关性,预测其影响乳腺癌进展的分子机制。方法从癌症基因组图集(the cancer genome atlas,TCGA)数据库下载乳腺癌数据集,获得CCDC69基因表达谱和临床信息。分析CCDC69在乳腺癌组织和正常乳腺组织中的表达情况;分析CCDC69的表达量与乳腺癌患者临床特征及预后之间的相关性。采用基因富集分析(GSEA)预测CCDC69可能参与的相关信号通路。结果CCDC69在乳腺癌组织中表达量较正常乳腺组织低(P<0.001);CCDC69表达量与乳腺癌患者年龄(P=0.020)和肿瘤体积(P=0.027)相关。CCDC69低表达的患者总体生存期短于CCDC69高表达的患者(P=0.004),其低表达是影响乳腺癌患者预后的独立因素(P=0.010)。CCDC69与MYC信号通路、E2F信号通路、未折叠蛋白反应、糖酵解基因集负相关。结论CCDC69可能是乳腺癌发生发展过程中的抑癌基因,有望成为乳腺癌潜在的治疗靶点和预后指标。
Objective To investigate the expression of CCDC69 in breast cancer and its association with clinical features and prognosis of breast cancer patients,and to predict the role of CCDC69 in the development of breast cancer.Methods Breast cancer datasets were downloaded from the cancer genome atlas(TCGA)to obtain the CCDC69 gene expression profiles and clinical information.The expression levels of CCDC69 in breast cancer tissues and normal breast tissues were compared,and the correlations of CCDC69 expression levels with clinicopathological parameters and their impact on prognosis were analyzed.Gene enrichment analysis(GSEA)was used to predict the possible pathways regulated by CCDC69 in breast cancer.Results CCDC69 in breast cancer tissues was under-expressed compared with normal breast tissues(P<0.001),and low expression of CCDC69 was an independent risk factor affecting the prognosis of patients with breast cancer.CCDC69 expressions were associated with age(P=0.020)and tumor size(P=0.027).The overall survival of patients with low expressions of CCDC69 was shorter than that of patients with high expressions of CCDC69(P=0.004).CCDC69 was negatively correlated with MYC signaling pathway,E2F signaling pathway,unfolded protein response and glycolysis gene sets.Conclusions CCDC69 may play a role as a tumor suppressor gene involved in the occurrence and development of breast cancer,and it can be potentially used as a therapeutic target and prognostic indicator.
作者
刘显胜
王振国
高温杰
于晓双
任贵兵
IJU Xiansheng;WANG Zhenguo;GAO Wenjie;YU Xiaoshuang;REN Guibing(Logistics University of People's Armed Police Force,Tianjin 300309,China;Department of Medical Research,Characteristic Medical Center of People's Armed Police Force,Tianjin 300162,China;Department of Oncology,Characteristic Medical Center of People's Armed Police Force,Tianjin 300162,China)
出处
《武警医学》
CAS
2019年第10期890-893,896,共5页
Medical Journal of the Chinese People's Armed Police Force
基金
天津市科技计划项目(15ZXLCSY00040)
